Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cantor Fitzgerald
Chubb
Julphar
McKesson
Covington
QuintilesIMS
Express Scripts
Farmers Insurance
Cipla

Generated: May 27, 2018

DrugPatentWatch Database Preview

TIKOSYN Drug Profile

or, see our see our flat-rate plans

« Back to Dashboard

When do Tikosyn patents expire, and when can generic versions of Tikosyn launch?

Tikosyn is a drug marketed by Pfizer and is included in one NDA. There is one patent protecting this drug and one Paragraph IV challenge.

This drug has fifty-four patent family members in forty-six countries.

The generic ingredient in TIKOSYN is dofetilide. There are eleven drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the dofetilide profile page.
Drug patent expirations by year for TIKOSYN
Pharmacology for TIKOSYN
Drug ClassAntiarrhythmic
Synonyms for TIKOSYN
(Dofetilide) N-[4-(2-{[2-(4-Methanesulfonylamino-phenyl)-ethyl]-methylamino}-ethoxy)-phenyl]-methanesulfonamide
1-(4-methanesulfonamidophenoxy)-2-(N-(4-methanesulfonamidophenethyl)-N-methylamine)ethane
1-(4-Methanesulphonamidophenoxy)-2-[N-(4-methanesulphonamidophenethyl)-N-methylamino]ethane
1-(4-Methansulphonamidophenoxy)-2-[N-(4-methanesulphonamidophenethyl)-N-methylamino]ethane
1-MSPMPE
115256-11-6
256D116
A803396
AB0004775
AB00639976_09
AB00639976-06
AB00639976-08
AB2000201
AC-385
AC1L2FYH
AC1Q6VUS
ACT04222
AK161932
AKOS005259921
Ambap115256-11-6
AN-15862
API0002471
BC660134
BCP0726000009
BCP9000619
BDBM50031720
beta-((p-Methanesulfonamidophenethyl)methylamino)methanesulfono-p-phenetidide
C-22372
C07751
C19H27N3O5S2
CAS-115256-11-6
CC-27363
CCG-101037
CHEBI:4681
CHEMBL473
CPD000466333
CS-2200
CTK8F9356
D00647
D0NW3X
DB00204
Dofetilida
Dofetilida [INN-Spanish]
Dofetilide
Dofetilide (JAN/USAN/INN)
Dofetilide (Tikosyn)
Dofetilide [USAN:BAN:INN]
Dofetilide [USAN:USP:INN:BAN]
Dofetilide, >=98% (HPLC)
Dofetilide, United States Pharmacopeia (USP) Reference Standard
Dofetilide;
Dofetilide(Tikosyn)
Dofetilidum
Dofetilidum [INN-Latin]
DSSTox_CID_26433
DSSTox_GSID_46433
DSSTox_RID_81610
DTXSID5046433
FC0019
FT-0631076
GTPL2604
HMS2051N14
HMS2089F03
HMS2232H19
HMS3261G03
HMS3370B18
HMS3393N14
HMS3655A17
HSDB 7927
HY-B0232
I06-0340
I881
IXTMWRCNAAVVAI-UHFFFAOYSA-N
J-003271
KB-09147
KS-00000XNN
LS-90151
Methanesulfonamide, N-(4-(2-(methyl(2-(4-((methylsulfonyl)amino)phenoxy)ethyl)amino)ethyl)phenyl)
Methanesulfonamide, N-(4-(2-(methyl(2-(4-((methylsulfonyl)amino)phenoxy)ethyl)amino)ethyl)phenyl)-
MFCD00869707
MLS000759442
MLS001424185
MLS006010154
MolPort-003-847-012
MRF-0000317
N-(4-(2-(methyl(2-(4-(methylsulfonamido)phenoxy)ethyl)amino)ethyl)phenyl)methanesulfonamide
n-(4-(2-{2-(4-(methanesulphonamido)phenoxyl)-n-methylethylamino}ethyl)phenyl)-methanesulphonamide
N-(4-{2-[methyl(2-{4-[(methylsulfonyl)amino]phenoxy}ethyl)amino]ethyl}phenyl)methanesulfonamide
N-[4-(2-{[2-(4-methanesulfonamidophenoxy)ethyl](methyl)amino}ethyl)phenyl]methanesulfonamide
N-[4-(2-{[2-(4-methanesulfonylamino-phenoxy)-ethyl]-methyl-amino}-ethyl)-phenyl]-methanesulfonamide
N-[4-(2-{[2-(4-Methanesulfonylamino-phenyl)-ethyl]-methyl-amino}-ethoxy)-phenyl]-methanesulfonamide (dofetilide)
N-[4-(2-{[2-(4-Methanesulfonylamino-phenyl)-ethyl]-methyl-amino}-ethoxy)-phenyl]-methanesulfonamide (UK-68798)
N-[4-(2-{[2-(4-METHANESULFONYLAMINO-PHENYL)-ETHYL]-METHYL-AMINO}-ETHOXY)-PHENYL]-METHANESULFONAMIDE DOFETILIDE
N-[4-(2-{2-[4-(methanesulphonamido)phenoxyl]-N-methylethylamino}ethyl)phenyl]-methanesulphonamide
N-[4-[2-[2-(4-methanesulfonamidophenyl)ethyl-methylamino]ethoxy]phenyl]methanesulfonamide
N-[4-[2-[2-[4-(methanesulfonamido)phenoxy]ethyl-methyl-amino]ethyl]phenyl]methanesulfonamide
N-[4-[2-[2-[4-(methanesulfonamido)phenoxy]ethyl-methylamino]ethyl]phenyl]methanesulfonamide
N-[4-[2-[methyl-[2-[4-(methylsulfonylamino)phenoxy]ethyl]amino]ethyl]phenyl]methanesulfonamide
N-[4-[2-[Methyl[2-[4-[(methylsulfonyl)amino]phenoxy]ethyl]amino]ethyl]phenyl]methanesulfonamide
NC00287
NCGC00164549-01
NCGC00164549-02
NCGC00261036-01
OR073605
OR205686
R4Z9X1N2ND
s1658
SAM001246621
SC-76467
SCHEMBL16135
SMR000466333
ST24046670
Tikosyn (TN)
Tikosyn, UK68798, Dofetilide
Tikosyn;UK68798
TL8000450
Tox21_112178
Tox21_112178_1
Tox21_500351
UK 68,798
UK 68789
UK 68798
UK-68,798
UK-68798
UK68789
UK68798
UNII-R4Z9X1N2ND
Xelide
ZINC596731

US Patents and Regulatory Information for TIKOSYN

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Pfizer TIKOSYN dofetilide CAPSULE;ORAL 020931-001 Oct 1, 1999 AB RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Pfizer TIKOSYN dofetilide CAPSULE;ORAL 020931-002 Oct 1, 1999 AB RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Pfizer TIKOSYN dofetilide CAPSULE;ORAL 020931-003 Oct 1, 1999 AB RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

or, see our see our flat-rate plans

Expired US Patents for TIKOSYN

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Pfizer TIKOSYN dofetilide CAPSULE;ORAL 020931-003 Oct 1, 1999 ➤ Try a Free Trial ➤ Try a Free Trial
Pfizer TIKOSYN dofetilide CAPSULE;ORAL 020931-001 Oct 1, 1999 ➤ Try a Free Trial ➤ Try a Free Trial
Pfizer TIKOSYN dofetilide CAPSULE;ORAL 020931-002 Oct 1, 1999 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for TIKOSYN
Drugname Dosage Strength RLD Submissiondate
➤ Subscribe Capsules 0.125 mg, 0.25 mg, and 0.5 mg ➤ Subscribe 2014-05-01

or, see our see our flat-rate plans

Supplementary Protection Certificates for TIKOSYN

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
00002 Netherlands ➤ Try a Free Trial PRODUCT NAME: DOFETILIDE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT; REGISTRATION NO/DATE: EU/1/99/121/001 - EU/1/99/121/015 19991129
00C/005 Belgium ➤ Try a Free Trial PRODUCT NAME: DOFETILIDE; REGISTRATION NO/DATE: EU/1/99/121/001 19991129
C/GB00/005 United Kingdom ➤ Try a Free Trial PRODUCT NAME: DOFETILIDE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REGISTERED: UK EU/1/99/121/001 19991129; UK EU/1/99/121/002 19991129; UK EU/1/99/121/003 19991129; UK EU/1/99/121/004 19991129; UK EU/1/99/121/005 19991129; UK EU/1/99/121/006 19991129; UK EU/1/99/121/007 19991129; UK EU/1/99/121/008 19991129; UK EU/1/99/121/009 19991129; UK EU/1/99/121/010 19991129; UK EU/1/99/121/011 19991129; UK EU/1/99/121/012 19991129; UK EU/1/99/121/013 19991129; UK EU/1/99/121/014 19991129; UK EU/1/99/121/015 19991129
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Express Scripts
McKinsey
Julphar
Queensland Health
Healthtrust
Baxter
Johnson and Johnson
Cantor Fitzgerald
Daiichi Sankyo

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.